Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Descending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00310-0625-60 00310-0625 SELUMETINIB KOSELUGO 25.0 mg/1 Chemotherapy MEK Inhibitor MEK 1/2 Oral April 16, 2020 In Use
00409-0365-01 00409-0365 DOCETAXEL Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous June 28, 2021 In Use
00409-1732-01 00409-1732 DOCETAXEL ANHYDROUS Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous June 28, 2021 In Use
00409-4235-01 00409-4235 DOCETAXEL Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous June 28, 2021 In Use
00409-5068-01 00409-5068 DOCETAXEL Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous June 28, 2021 In Use
55150-0378-01 55150-0378 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous June 25, 2021 In Use
55150-0379-01 55150-0379 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous June 25, 2021 In Use
55150-0380-01 55150-0380 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous June 25, 2021 In Use
62332-0565-30 62332-0565 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
62332-0565-90 62332-0565 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use

Found 10,000 results in 4 milliseconds — Export these results